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1Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland,
2Institute of Laboratory Medicine, Triemli Hospital, Zurich, Switzerland, 3Department of Medical Oncology and
Hematology, University Hospital and University of Zurich, Zurich, Switzerland and 4Department of Internal Medicine,
Triemli Hospital, Zurich, Switzerland
Received February 14, 2020; Revised March 25, 2020; Editorial Decision March 26, 2020; Accepted April 09, 2020
ABSTRACT
Erythropoietic protoporphyria (EPP) is a rare genetic
disease in which patients experience acute photo-
toxic reactions after sunlight exposure. It is caused
by a deficiency in ferrochelatase (FECH) in the heme
biosynthesis pathway. Most patients exhibit a loss-
of-function mutation in trans to an allele bearing a
SNP that favors aberrant splicing of transcripts. One
viable strategy for EPP is to deploy splice-switching
oligonucleotides (SSOs) to increase FECH synthe-
sis, whereby an increase of a few percent would pro-
vide therapeutic benefit. However, successful appli-
cation of SSOs in bone marrow cells is not described.
Here, we show that SSOs comprising methoxyethyl-
chemistry increase FECH levels in cells. We conju-
gated one SSO to three prototypical targeting groups
and administered them to a mouse model of EPP in
order to study their biodistribution, their metabolic
stability and their FECH splice-switching ability. The
SSOs exhibited distinct distribution profiles, with in-
creased accumulation in liver, kidney, bone marrow
and lung. However, they also underwent substantial
metabolism, mainly at their linker groups. An SSO
bearing a cholesteryl group increased levels of cor-
rectly spliced FECH transcript by 80% in the bone
marrow. The results provide a promising approach to
treat EPP and other disorders originating from splic-
ing dysregulation in the bone marrow.
INTRODUCTION
Erythropoietic protoporphyria (EPP; OMIM # 177000) is
a rare autosomal recessive disorder (1), that is caused by
deficiency in the heme biosynthesis enzyme ferrochelatase
(FECH, EC 4.99.1.1) (Figure 1A) (2,3). During heme
biosynthesis, FECH catalyses the incorporation of iron into
protoporphyrin IX (PPIX) to form heme. With over 80%
of heme produced in red blood cells progenitors, the bone
marrow is the major site of biosynthesis. Kidneys and liver
are also minor sites of heme biosynthesis (4). A lack of
FECH means that PPIX continuously accumulates during
erythroid maturation, resulting in PPIX circulating in red
blood cells of the bloodstream. Upon short exposure to vis-
ible light, PPIX produces reactive oxygen species leading to
lipid peroxidation, cell membrane damage and inflamma-
tion. This causes patients to suffer from burn-like injuries of
the endothelial cells of the blood vessels and the surround-
ing tissue, associated with acute severe pain; some will de-
velop hepatic complications with deposits of PPIX crystals
and are at risk of liver failure (5,6).
EPP in almost all patients is associated with an alteration
in both FECH alleles. On one, FECH expression is atten-
uated by a deleterious mutation (7); on the other, a single
nucleotide polymorphism (SNP) in intron 3 (c.315-48T>C)
bolsters the use of a cryptic 3′ splice site, that produces an
aberrant mRNA incorporating additional sequence preced-
ing exon 4 (Figure 1B). Stop codons in this sequence re-
sult in degradation of the transcript by nonsense-mediated
mRNA decay (NMD) (3). The combined effects of these al-
leles are reduced levels (>65%) of FECHactivity, which ren-
ders patients symptomatic. As the c.315-48C allele turns a
carrier of a loss-of-function (LoF) allele from asymptomatic
to symptomatic, a splice-switching oligonucleotide (SSO)
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Figure 1. A single-nucleotide polymorphism causes aberrant splicing of FECHmRNA. (A) Biosynthesis of heme from glycine and succinyl CoA comprises
eight sequential steps occurring in the cytosol and in the mitochondria. FECH is the last enzyme of the pathway and catalyzes the incorporation of iron
into protoporphyrin IX. EPP patients present a dramatic decrease of FECH, resulting in reduced heme production and accumulation of protoporphyrin
IX in cells. (B) FECH pre-mRNA contains a weak cryptic splice site in intron 3 (c.315-63.) close to a single nucleotide polymorphism (c.315-48T in healthy
individuals). Utilization of this splice site yields a transcript which is a substrate for NMD. This aberrant splicing is increased by the c.315-48C variant
which is present in trans to a hypomorphic FECH allele in 95% of EPP patients and in a few percent of the general population. (C) The transgenic murine
Emi model shows the aberrant splicing of human patients, but additionally skips exon 3 in most of the FECH transcripts.
is a viable means to restore sufficient FECH expression
for haplo-sufficiency in patients. SSOs composed of LNA
(locked nucleic acids) and morpholino chemistries are re-
ported to correct the aberrant splicing of the FECHmRNA
ex vivo in patients’ blood cells (8,9), but this approach has
not yet been described in vivo.
SSOs are oligonucleotides of about 20 nucleotides
(nt) in length, that bind to a pre-mRNA and modu-
late its splicing (10,11). Several are in development to
treat rare diseases caused by aberrant RNA maturation,
reading-frame shifts, or exon skipping. The most promi-
nent example is nusinersen, an approved treatment of
spinal muscular atrophy (SMA) that mediates exon in-
clusion in the SMN2 pre-mRNA (12,13). Nusinersen is
composed of phosphorothioated (PS)-2′-O-methoxyethyl
(MOE)-ribonucleotides (14), which endow the drug with
high metabolic stability and extended distribution in vivo.
PS-MOE oligonucleotides traffic to the liver, kidneys and
spleen at therapeutically-useful concentrations after sys-
temic administration (15,16). They have also been de-
tected in bone marrow in rodents, though SSOs of vari-
ous chemistries were inactive in the bone marrow of a re-
porter mouse model (17), possibly due to poor cellular-
uptake and/or to the high turnover of red blood cell progen-
itors (18). This obstacle impacts an SSO strategy for EPP,
but may be addressable thanks to advances in the use of
conjugated groups for organ-targeted delivery (e.g.GalNAc
sugars (19)).
We recently developed a transgenic mouse model for
human EPP (Emi mouse) (20), incorporating the c.315-
63 cryptic splice site of FECH from human intron 3. The
mouse displays the aberrant splicing of exon 4; however, for
reasons unknown, exon 3 is deleted from most transcripts
(Figure 1C). Hence, SSOs that correct the aberrant splic-
ing of the transgene will not increase levels of FECH ac-
tivity, nor attenuate levels of circulationg PPIX. Here, we
describe a 22-nt PS-MOE SSO, which binds to the c.315-
48 SNP and corrects splicing of FECH transcripts in cells
and in the Emi mouse. Using different linker strategies,
we conjugated the SSO to three targeting moieties: thio-
cholesterol (21,22), stearic acid (23) and a bone marrow-
homing peptide (24). We first assessed their metabolic sta-
bility in vitro, and then their distribution, metabolism and
splice-switching activity in Emi/wt heterozygous mice us-
ing mass spectrometry and chemical ligation PCRmethods.
Whereas the oligonucleotide moiety was metabolically sta-
ble, the conjugated groups underwent degradation in vitro
and in vivo, albeit through different pathways. The conju-
gates also altered in vivo-distribution and splice-switching
activity of the SSO. The parent SSO was detected in all tis-
sues tested, and showed splice-switching of FECH RNA in
liver, kidney and lung. The cholesterol group increased liver
transport by seven-fold, but this SSO was not more potent
than the parent SSO. The stearic-acid conjugate increased
liver delivery by a lesser degree, but raised FECH transcript
levels there by 60%. Notably, the homing-peptide increased
bone marrow accumulation by seven-fold, but it hardly af-
fected FECH splicing, whereas the cholesterol group, which
did not improve transport to bone marrow, increased levels
of the correct FECH transcript by 80%.
This study of splice-switching oligonucleotide conjugates
complements recent investigations of the pharmacokinetic
and pharmacodynamic properties of antisense and siRNA
conjugates (25,26). The results reinforce the notion that
increased delivery does not necessarily translate to im-
proved potency. They also advance the prospect of an
oligonucleotide-based therapy for correction of the FECH
splicing defect at the origin of EPP.
MATERIALS AND METHODS
Small scale synthesis of MOE-PS splice-switching oligonu-
cleotides
Small scale oligonucleotide synthesis was conducted on
a MerMade 12 synthesizer (BioAutomation Inc) on a
50 nmol scale on 500 Å UnyLinker CPG (ChemGenes)
4660 Nucleic Acids Research, 2020, Vol. 48, No. 9
with standard synthesis conditions. DMT cleavage was
accomplished with a solution of 3% dichloroacetic acid
in dichloromethane (V/V). 2′-O-MOE phosphoramidites
(ThermoFisher Scientific) were prepared at 0.08 M con-
centration in dry acetonitrile. 5-(Benzylthio)-1H-tetrazole
(Carbosynth) was used at 0.24 M concentration in dry
acetonitrile to activate the phosphoramidites for cou-
pling. Sulfurization was carried out with a 0.05 M so-
lution of 3-((N,N-dimethylaminomethylidene)amino)-3H-
1,2,4-dithiazole-5-thione (Glen Resarch #40-4037) in a
1:1 mixture of pyridine/acetonitrile. Capping of failed se-
quences was achievedwith acetic anhydride in tetrahydrofu-
ran (THF) and 16% N-methylimidazole in THF. Following
cycle parameters were used: Deblock 2× 60 s; Coupling 2×
180 s; Sulfurization 1 × 150 s; Capping 2 × 50 s. Analytical
data are provided in Supplementary Figure S1.
Synthesis of chemical ligation-qPCR primers
Primers were synthesized on aMerMade 12 synthesizer fol-
lowing a similar procedure withminormodifications to that
described in the initial publication (27). Analytical data are
provided in Supplementary Figure S2.
Large scale synthesis of ORN1 and of conjugates ORNst,
ORN84 and ORNch
Large scale synthesis was conducted on aMerMade 12 syn-
thesizer with minor changes compared to the small-scale
procedure: sulfurization reagent was prepared at 0.1 M in-
stead of 0.05 M. Modified cycle parameters were used: De-
block 2 × 60 s; Coupling 1 × 600 s; Sulfurization 1 × 600 s;
Capping 2 × 100 s (see also Supplementary Methods). An-
alytical data of batches used for in vivo work are provided
in Supplementary Figure S3.
Oligonucleotide screening in the COS-7 FECH-C minigene
system
COS-7 cells were kept in culture at 37◦C, 5% CO2. Cells
were plated at 140 000 cells/well in a 24-well plate in 1 ml
DMEM-GlutaMax (ThermoFisher #10566016) containing
10% fetal bovine serum for 18 h prior to plasmid trans-
fection. 700 ng of the FECH-C minigene (28) was trans-
fected using XtremeGENE HP DNA transfection reagent
(Sigma-Aldrich #XTGHP-RO) as per manufacturer’s in-
structions with a ratio of 2.5 l transfection reagent/g
plasmid DNA. Oligonucleotides were transfected 4 h af-
ter the plasmid using Lipofectamine™ 2000 (ThermoFisher,
#11668027) following manufacturer’s instructions. 24 h
prior to lysis and RNA extraction, emetine (Sigma-Aldrich
#E2375) was added in each desired well at a final concen-
tration of 3 M.
Cells were washed with Dulbecco’s phosphate-buffered
saline (DPBS) and RNA extraction was carried out using
Qiagen RNEasy kit according to manufacturer’s instruc-
tions with the inclusion of two DNAse-treatment steps (Qi-
agen #74106, #79254). cDNAwas prepared using the High
Capacity cDNA RT kit (Applied Biosystems #4374966)
in accordance with the manufacturer’s instructions. PCR
primers specific for the minigene were used: Forward 5′-GC
TCTCTACCTGGTGTGTGG-3′, Reverse 5′-GACAAT
TCA TCCAGCAGC TTC-3′. A PCRmix containing 1 l
FW primer (10 M stock), 1 l RV primer (10 M stock),
1 l dNTPs mix (Promega #U1515), 5 l 10× DreamTaq
Buffer (ThermoFisher #EP0703), 0.25 l DreamTaq DNA
Polymerase (ThermoFisher #EP0703) and 40.75 l ultra-
purewater was prepared andmixedwith 1l of cDNA solu-
tion diluted 1/3 in water. PCR program: 95◦C, 1 min; 30 cy-
cles (95◦C, 30 s – 60◦C, 30 s – 68◦C, 30 s); 68◦C, 5 min. PCR
products were loaded on a 2%agarose gel and bands quanti-
fied using ImageJ software. Ratios were expressed as: inten-
sity of the aberrant amplicon band / (intensities of aberrant
+ correct bands).
Endogenous splicing correction and correct FECH transcript
evaluation in K562 cells
K562 cells were kept in culture at 37◦C, 5% CO2. Cells
were plated at 200 000 cells/well in a 24-well plate in 0.5 ml
IMDE (Sigma #I3390) containing 10% fetal bovine serum
and 4 mM L-glutamine (Sigma #G7513). Oligonucleotides
were transfected 1.5 h after plating using Lipofectamine™
2000 (ThermoFisher, #11668027) following manufacturer’s
instructions. Emetine (Sigma-Aldrich #E2375) was added
in each desired well at a final concentration of 3 M 2.5 h
hours after oligonucleotide treatment and 22 h before lysis
and RNA extraction.
Cells were washed with DPBS and RNA extraction
was carried out using Qiagen RNEasy kit according
to manufacturer’s instructions (Qiagen #74106, #79254).
cDNA was generated using PrimeScript RT kit (Takara
#RR037A). For semi-quantitative RT-PCR; PCR primers
specific for human FECH exon 2–exon 4 transcripts were
used: Forward 5′-CAC AGA AAC AGC CCA GCA TG-
3′, Reverse 5′-GAC AAT TCA TCC AGC AGC TTC-
3′. A PCR mix containing 1.25 l FW primer (10 M
stock), 1.25 l RV primer (10 M stock), 0.125 l dNTPs
mix (Promega #U1515), 0.25 l 5× Q5 Polymerase Buffer
(NEB #M0491), 0.25 l Q5 DNA Polymerase (NEB
#M0491) and 15.75 l ultrapure water was prepared and
mixed with 1 l of cDNA solution. PCR program: 98◦C,
30 s; 33 cycles (98◦C, 10 s – 58◦C, 20ms – 72◦C, 2 s);
72◦C, 2 min. PCR products were loaded on a 2% agarose
gel and bands quantified using ImageJ software. Ratios
were expressed as: intensity of the aberrant amplicon
band/(intensities of aberrant + correct bands). Biological
replicates are presented in Supplementary Figure S4. For
RT-qPCR, a primer pair for correctly spliced FECH tran-
script was used. A mix containing 4 l SYBR Mix 2×,
0.33 l primer pair (stock of 10 M each in water) and
3.17 l ultrapure water was prepared and mixed with 0.5 l
cDNA solution. Primers were purchased from Microsynth
(Balgach, Switzerland) and stored as pairs at 10 M each.
Samples were run in technical triplicates and GAPDH was
used as housekeeping control. Fold change calculations for
the correctly spliced FECH transcript were made by com-
paring each treatment group with the mock group. FECH
FW primer: 5′-CCT ATT CAG AAT AAG CTG GCA
CC-3′; FECH RV primer: 5′-CCT GCT TGG AAG TCC
ATATCTTG-3′. GAPDHFWprimer: 5′-AGGTCGGTG
TGA ACG GAT TTG-3′; GAPDH RV primer: 5′-TGT
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AGA CCA TGT AGT TGA GGT CA-3′. Statistical anal-
ysis (multiple t-tests) was conducted with GraphPad Prism
v7. software.
Western blotting experiments in K562 cells
K562 cells were grown as above. Cells were plated at 100
000 cells/well in a 24-well plate in 1 ml medium and
oligonucleotides transfected 1.5 h after plating using Lipo-
fectamine™ 2000. K562 cells were lysed 24 or 48 h af-
ter treatment in 100 l RIPA buffer (ThermoFisher Sci-
entific) supplemented with protease inhibitor (cOmplete,
Roche). Lysates were incubated on ice for 30 min prior
to brief needle sonication (25% amplitude, 6 s pulse), fol-
lowed by centrifugation at 12 000 g for 15 min. Super-
natants were collected and protein concentration was as-
sessedwith the Pierce BCAprotein assay kit (ThermoFisher
Scientific). 10 g of protein from each sample was de-
naturated in Laemmli buffer (BioRad) containing 7% -
mercaptoethanol, and loaded onto 4–20% pre-cast TGX
gels (BioRad) for electrophoresis. Protein transfer onto ni-
trocellulose membranes (GE Life Sciences) was carried out
for 90 min at 25 W in a Mini Trans-Blot Electrophoretic
Transfer Cell (BioRad). Membranes were blocked for 3 h
with 5% (w/v) nonfat dry milk in 0.05% Tween 20 in PBS
(PBS-T) and were incubated overnight at 4◦C with the pri-
mary antibody. Membranes were washed three times with
0.05% PBS-T, followed by incubation with the secondary
antibody for 1 h in 5% milk in 0.05% PBS-T. After washing
with 0.05% PBS-T, signal was detected with the ECL Prime
reagent (GE Life Sciences) in a ChemiDoc XRS+ station
(BioRad).
Chemiluminescence was quantified using the ImageJ
software. Ratios were calculated and graphical output and
statistical analysis (one-way ANOVA) was conducted with
GraphPad Prism v7. software. Biological replicates are pre-
sented in Supplementary Figure S5. List of primary anti-
bodies used: FECH (mouse, SantaCruz, sc-377377, 1/500
dilution), GADPH (mouse, Proteintech, 60004-1-Ig, 1/10
000 dilution) and the corresponding secondary antibody:
anti-mouse (goat, Seracare, 5220-0341, 1/10 000 dilution).
Stability assay in mouse plasma
5 nmol of in-vivo ready oligonucleotides (UV purity > 99%,
sodium salt) were spiked in 200 l of mouse K2-EDTA
plasma (BioIVT #MSE02PLK2Y2N) and 20 l aliquots
were taken immediately after mixing, and after 5 min, 15
min, 30 min, 1 h, 2 h, 4 h, 6.5 h, 22 h and 26 h incuba-
tion and gentle shaking at 37◦C. Aliquots were immedi-
ately quenched with 350 l OTX Clarity Lysis buffer (Phe-
nomenex #AL0-8579) and frozen at –20◦C. Clean-up was
conducted all at once using the Clarity® OTX Extraction
kit (Phenomenex #KS0-9253) according to manufacturer’s
procedure for biological fluids with the following adjust-
ments: formulation of all buffers with ammonium acetate in
substitution of sodium phosphate; dissolution of the final
eluate after evaporation to dryness in 100 l of TE buffer
pH 8.0. Reconstituted samples were analysed qualitatively
by LC–MS (Agilent 1200/6130 system) equipped with a
Waters Acquity OST C-18 column.
Animal injections
The oligonucleotides and oligonucleotide conjugates
were injected subcutaneously into mice of the B6.Cg-
Fechtm1.1(FECH*)Emi line (Emi for short) of Emi/wt genotype
at a dose of 50 mg/kg. Four doses were administered
over a period of two weeks. Weight of the mice was de-
termined prior to each injection to monitor any adverse
weight loss due to oligonucleotide injection. 24 h after
the last injection, the mice were weighed and euthanized
by carbon dioxide inhalation. Blood was withdrawn
from the posterior vena cava of each mouse and used to
prepare heparinized plasma. Liver, spleen, kidneys, lungs,
heart, brain, quadriceps muscle were collected and snap
frozen in liquid nitrogen. Bone marrow was isolated from
femurs and tibiae by flushing the bones with cell culture
medium (RPMI +10% FBS). Bone marrow cell pellets
were frozen at –80◦C till used for uptake studies or RNA
isolation. Tissue samples were ground into a fine powder
in liquid nitrogen and separate samples were immediately
aliquoted for dissolution in OTXLysis buffer (Phenomenex
#AL0-8579) for uptake and metabolite study, or in Trizol
(ThermoFisher #1559606) for RNA extraction. All animal
experiments were conducted in accordance with local laws
under the license number ZH115/16.
CL-qPCR in tissues
The ground tissue powder was suspended in 10
volumes/weight OTX Lysis Buffer, briefly needle-sonicated
and centrifuged for 30 s at 14 000 rpm. Supernatants were
collected, diluted at 1/750 in ultrapure water, and used for
analysis. CL-qPCR was carried out following the protocol
from Boos et al. (27), with minor modifications. For each
tissue and each compound, a calibration curve was gener-
ated and run along with the samples. Mix composition for
Chemical Ligation: 0.1 l PS primer (10 M stock), 0.1 l
BPS primer (10 M primer), 1 l Poly A (GE Healthcare
#27411001, 1 mg/ml), 1 l 10× Buffer with MgCl2 (Roche
#12032902001) and 5.8 l ultrapure water, mixed with 2 l
diluted lysate. Chemical ligation was run for 1 h at 33◦C.
qPCR was run on a LC480 device (Roche). A qPCR mix
containing 0.15 l FW primer (10 M stock), 0.15 l RV
primer (10 M stock), 0.13 l BHQ primer (28.28 M
stock), 0.15 l dNTPs mix (ThermoFisher #10297018), 1
l 10× Buffer with MgCl2 (Roche #12032902001), 0.1 l
10× FastTaq Polymerase (Roche #12032902001) and 6.32
l ultrapure water was prepared and mixed with 2 l of
chemical ligation reaction mixture. qPCR program was as
follows: 10 min, 95◦C, 50 cycles (3 s/95◦C – 30 s/55◦C – 10
s/72◦C). Concentrations in tissues were obtained through
interpolation from the calibration curves and expressed in
ng oligonucleotide/mg tissue for each mouse.
Oligonucleotide extraction from tissue lysates for LC–MS
analysis
Ground tissues were suspended in 10 volumes/weight OTX
Lysis Buffer, briefly needle-sonicated and centrifuged for 30
s at 14 000 rpm. Supernatants were collected for oligonu-
cleotide clean-up and directly processed with the Clarity®
OTX Extraction kit (Phenomenex #KS0-9253) according
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to manufacturer’s procedure for tissues with the follow-
ing adjustments: formulation of all buffers with ammo-
nium acetate in substitution of sodium phosphate; dis-
solution of the final eluate after evaporation to dryness
in 100 l of TE buffer pH 8.0 instead of water. Pro-
teinase K pre-treatment was necessary for successful recov-
ery of the oligonucleotide with liver samples coming from
mice treated with cholesteryl conjugate ORNch; this pre-
treatment was used for all subsequent ORNch tissues.
RNAextraction frommouse tissues andRT-qPCR for correct
FECH transcript
The ground tissue powder for each sample was dissolved
in Trizol reagent (10–50 mg tissue/ml Trizol) and RNAwas
extracted following manufacturer’s instructions. RNA sam-
ples were subjected to an extra clean-up step and DNase
treatment using Qiagen RNeasy kit as per manufacturer’s
instructions (Qiagen #74106, #79254). cDNA was gener-
ated using PrimeScript RT kit (Takara #RR037A). qPCR
was run on a LC480 device (Roche) with the KAPA SYBR
Fast qPCR kit (#KK4618). A qPCR mix containing 4 l
SYBRMix 2×, 0.33 l primer pair (stock of 10 Meach in
water) and 3.17 l ultrapure water was prepared and mixed
with 0.5 l cDNA solution. Primers were purchased from
Microsynth (Balgach, Switzerland) and stored as pairs at
10 M each. Samples were run in technical triplicates and
GAPDH was used as housekeeping control. Fold change
calculations for the FECH correctly spliced transcript were
made by comparing each treatment group with the saline
group. FECH FW primer: 5′-CCT ATT CAG AAT AAG
CTG GCA CC-3′; FECH RV primer: 5′-GGG GAT CCG
CCT CCA ATC-3′. GAPDH FW primer: 5′-AGG TCG
GTG TGA ACG GAT TTG-3′; GAPDH RV primer: 5′-
TGT AGA CCA TGT AGT TGA GGT CA-3′. Statisti-
cal analysis (multiple t-tests) and outlier removal (ROUT
method) were conducted with GraphPad Prism v7. soft-
ware.
RESULTS AND DISCUSSION
Identification of a lead SSO for FECH RNA splicing correc-
tion
As of yet, it is difficult to predict potent SSO sequences us-
ing computational methods (29,30). Therefore, the search
for an effective SSO typically begins by ‘walking’ empiri-
cally a set of overlapping sequences across exonic and in-
tronic regions in the region of the pathogenicmutation. This
approach identified nusinersen, which binds the ISS-N1 site
on SMN2 (13), and more recently, an effective SSO as a po-
tential treatment for familial dysautonomia (31).
We scanned regions on the FECH pre-mRNA close to
the c.315-48 polymorphism (Figure 2A; sequences in Sup-
plementary Information) for splice-switching activity by us-
ing a set of sequence-overlapping 19-nt MOE-PS oligonu-
cleotides. We elected to use MOE-PS SSOs because of their
successful use in clinical programs (www.ionispharma.com)
(32), their excellent safety record (32,33), their efficient dis-
tribution in vivo (15), the ease with which they can be elab-
orated with targeting groups or stereopure linkages (28).
We employed a mini-gene assay transiently expressing the
FECH-C variant in COS-7 cells, which we have described
previously (20). For each SSO, we calculated the fraction
of ‘correct’ (desired) transcripts on agarose gels after work-
up using RT-PCR. Since the aberrant transcript, at least
for the complete FECH gene, is degraded through non-
sense mediated mRNA decay (NMD) (3), we pre-treated
cells with emetine, a global inhibitor of translation that pre-
vents NMD (34) to ensure reliable measurements of aber-
rant transcript levels.Most SSOs showed some effect on tar-
get splicing, changing the fraction of correct transcripts by
a few percent in the desired direction (Figure 2B). Several
SSOs binding between residues 40–66 produced almost full
splice correction, and activity dropped away with sequences
binding upstream of position –50. In a round of optimiza-
tion for increased potency, we identified two 22-nt- and one
25-nt SSOs displaying equal or better activity than the afor-
mentioned LNA SSO (8), which we used as a control (Fig-
ure 2C, D). From these, ORN1 was selected as the lead
SSO.
Binding the c.315-48C SNP but not the aberrant splice site is
sufficient for splicing correction
We noted from the initial screen that the most active SSOs
covered the –48 SNP, but not necessarily the –63 aberrant
splice site. We tested a library of shorter (10-nt) MOE-
PS oligonucleotides (Figure 2E; Supplementary Table S1)
binding to the –63 and the –48 sites of FECH separately, in
order to pinpoint the nucleotides important for the activity
of the SSOs in the region of the SNP. One sequence bind-
ing at positions –45–54 altered the course of splicing signifi-
cantly, and three-nucleotide shifts upstream or downstream
resulted in loss of activity (Figure 2E). Co-treatments of
cells with SSOs blocking simultaneously the splice site (–
57–66) and the SNP (–45–54) did not produce synergistic
effects.
We and others (3) have observed that ratios of aber-
rant:correct FECH transcripts vary according to the geno-
type, the cell type and iron availability (35). With emetine
treatment to inhibit NMD of mRNA in lymphoblasts im-
mortalized from donors, we found approximately 30% and
60% of the FECH transcripts were aberrantly spliced for
the T/T (c.315-48T)- and C/C (c.315-48C)-homozygotes,
respectively (not shown). We observed the same ratios in
COS-7 cells transfected with the minigenes (Supplemen-
tary Figure S6) and approximately 15% aberrant splicing
in the K562 cell line, which is bone-marrow derived, and
has erythroid features (36); we confirmed the T/T genotype
of these cells by Sanger sequencing (Supplementary Figure
S7). Taken together, this implies that the outcome of FECH
splicing may depend upon a finely-tuned balance of pos-
itive and negative splicing regulatory elements. According
to Human Splicing Finder (37), the -48 SNP is embedded in
predicted binding sites for hnRNPA1, SRSF1 and SRSF2
alternative splice factors, and the T>C polymorphism may
create an Exon Inclusion Element (EIE) (38). An oligonu-
cleotide binding to the –45–54 locusmight lessen this activa-
tion, in a similar fashion to that described for the cblE type
of homocystinuria, where the c.309+469T>Cmutation cre-
ates an EIE and promotes the inclusion of a pseudo-exon
(39).
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Figure 2. Identification of splice-switching oligonucleotides (SSOs) targeting intron 3 of FECH pre-mRNA. (A) Binding sites for twenty 19-nt MOE-PS
SSOs in the region of the FECH c.315-48 polymorphism and the c.315-63 aberrant splice site. (B) Agarose gel showing relative amounts of aberrant and
correct transcripts after treatment with 50 nM concentrations of SSOs in COS-7 cells expressing a FECH-C minigene; LNA45-63 (9) is a positive control.
(C) Lead optimization: binding sites for 22 and 25-nt SSO analogs of selected SSOs from b). (D) Activity ofORNs 1–3 showing complete splice correction
at 10 nM concentration in the same assay. (E) Binding sites for ten 10-nt SSOs in the regions of the –63-splice site and the –48 polymorphism, and agarose
gels showing relative amounts of aberrant and correct transcripts from treatment at 50 nM concentration of COS-7 cells expressing a FECH-C minigene
with short SSOs; positive control is -45-63 LNA-SSO. Splicing correction obtained in the minigene experiment with single oligonucleotide treatment (left-
hand side) or cotreatments (right-hand side). In panels (A), (C) and (E), the ag labeled in red indicates the cryptic 3′ acceptor site, and the C labeled in red
the c.315-48 variant.
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It has not yet been possible to test ORN1 for its effects
on native FECH mRNA and protein, since transfectable
patient-derived (C/C)-cells expressing low levels of FECH
protein are unavailable, and we have so far been unable to
generate a model cell line using CRISPR-Cas based meth-
ods. Therefore, we assayedORN1 in K562 erythroleukemia
cells, expressing the T-variant of FECH, in which ORN1
binds its target with a G–U wobble at the site of the poly-
morphism. We included a fully complementary version of
the SSO (ORN1T) in the assay. Both SSOs showed splice-
switching activity (Figure 3A) and increased the levels of
the correctly spliced transcript by 25–30% (Figure 3B) and
FECH protein by ∼50% (Figure 3C).
Synthesis of MOE-PS SSOs conjugated with groups for tar-
geted delivery
MOE-PS oligonucleotides are delivered to bone marrow
after systemic administration in rodents (15,17) and in
man (see refs in (16)), however, MOE-PS SSOs were in-
active when tested in a mouse model for splicing of a re-
porter gene (17). Therefore, we conjugated ORN1 with
three prototypical functionalities that are reported to en-
hance delivery to selected tissues in vivo (Figure 4A):
stearic acid which increases circulation times due to al-
bumin binding (23) (ORNst); a heptapeptide residue that
homes to bone marrow and binds primitive stem cells (24)
(ORN84); and cholesterol which delivers single-stranded
and double-stranded oligonucleotides to bone marrow
(21,40,41) (ORNch). Stearic acid was conjugated as an
amide whereas the peptide and the cholesterol groups were
conjugated via thiol-maleimide chemistry (see Supplemen-
tary Methods) (42,43).
In vitro characterization of conjugate stability in plasma and
on albumin binding
MOE-PS oligonucleotides are highly resistant to nuclease-
mediated degradation in vivo (44,45), but less is known
about the metabolic stability of the conjugates and their
linkers. The thiosuccinimide linker of ORN84 and ORNch
has been widely used in the field of antibody drug conju-
gates but may undergo thiol-exchange reactions with cys-
teines of serum albumin (46) or glutathione (47). The pep-
tide ofORN84 is not modified to convey stability against hy-
drolases. Therefore, we examined the stability of the SSOs in
a plasma stability assay thatmimics conditions in the blood-
stream (48,49). We incubated the SSOs in mouse plasma
and removed aliquots periodically for analysis by liquid
chromatography–mass spectrometry (LC–MS).
ORN1 was highly high stable in plasma, though trace
amounts of a 3′ (n – 1) metabolite was detected after 26 h
(not shown). In contrast, all of the conjugates suffered some
degradation. The peptide moiety ofORN184 underwent se-
quential proteolysis from the C-terminus: metabolites miss-
ing one (B) and two amino-acids (C) were seen after 6.5
h, and (D) and (E) were identified after 26 h (Figure 4B).
The linker also underwent ring opening of the succinimide
(metabolite Y) after 1 h, and cleavage of the amide was
apparent after 6.5 h (metabolite Z). ORNch underwent a
similar albeit slower hydrolysis of the linker, producing two
products with the same mass (9411: ORNch+18), which we
assigned as ring-opened regioisomers (Y1 and Y2) (Figure
4C). The stearic acid conjugate ORNst showed only trace
amounts of degradation after 26 h (Figure 4D).
Distribution andmetabolism of FECHSSOs inmouse tissues
and organs
Recently, we engineered a murine model of EPP (Emi), in
which intron 3 of the mouse gene was replaced by the corre-
sponding human sequence bearing the c.315-48C polymor-
phism (20) (Figure 1C). Homozygous Emi/Emi mice were
not viable. However, viable Emi/wt mice contain one wild-
type allele and one allele of the EPP genotype which pro-
duces the same aberrant/correct splicing products as the
human c.315-48C allele. Unfortunately, this splicing pheno-
type was accompanied by an additional unanticipated splic-
ing defect - an almost complete skipping of exon 3, and thus
loss of FECH protein. Hence, the Emi model is unsuitable
for studying effects of SSOs on the disease phenotype, but is
amenable to investigations of the pharmacokinetics proper-
ties of SSOs and their effects on the amount of FECH tran-
scripts containing the extra 63 nucleotide sequence (Figure
1C).
SSOs were administered to Emi/wt mice twice a week
over two weeks similar to other published protocols us-
ing MOE-PS oligonucleotides (15,50–52). Mice were sac-
rificed 24 h after the last injection. No signs of toxicity
were apparent from measurements of total body weight,
liver/body weight and spleen/body weight ratios as well
as assessment of the general condition (not shown). Ac-
cumulation of SSOs in selected tissues was quantified us-
ing chemical ligation––qPCR (CL-qPCR) (27,53,54) (Fig-
ure 5A). This technique is particularly useful for quantifi-
cation of SSOs that are heavily modified and are not ampli-
fiable by polymerases. Standard calibration curves for the
four SSOs were generated in diluted lysate (Supplementary
Figure S8) and used to determine SSO concentrations in the
tissues of treated mice.
ORN1 was detected in all tissues except for brain and
muscle (Figure 5B). Consistent with previous studies (55),
the highest levels were found in kidney (178± 14 ng/mg tis-
sue) and liver (46±8 ng/mg tissue), followed by bone mar-
row (35 ± 12 ng/mg tissue), spleen (20 ± 3 ng/mg tissue)
and lung (10 ± 3 ng/mg tissue). Furthermore, the abso-
lute concentrations ofORN1measured using CL-qPCRare
in accordance with those determined using radio-labeled
oligonucleotides (15).ORNst showed a 2-fold higher uptake
in liver (84 ± 16 ng/mg tissue), in spleen (40 ± 12 ng/mg
tissue) and lung (17 ± 4 ng/mg tissue), and a slightly re-
duced accumulation in kidney. These findings are again con-
sistent with reports that siRNAs conjugated to hydropho-
bic fatty acids are transported to the liver at the expense
of kidney (25). ORNch showed 7-fold higher levels in liver
(341± 50 ng/mg tissue), a 2-fold increase in spleen (54± 12
ng/mg tissue) and a 60% decrease in kidney compared
to ORN1; the presence of ORNch in lung tissue was be-
low accurate detection. Again, this is consistent with the
findings of other groups using cholesteryl-siRNAs (23,56)
and single-stranded antisense–cholesteryl conjugates (57).
ORN84 showed an approximate 2-fold increase in liver (78
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Figure 3. Endogenous activity of the lead SSO ORN1 at RNA and protein levels in erythroleukemic K562 cells. (A) Activity of ORN1, ORN1T and two
randomized versions of ORN1 in K562 cells 24 h after transfection (ORN1 and ORN1T bind FECH mRNA in K562 cells with a G-U wobble and with
perfect complementarity, respectively). Aberrant transcripts were stabilized with 3 Memetine treatment. (B)ORN1 andORN1T selectively increase levels
of endogenous correctly spliced FECH transcripts in K562 cells as assayed by SYBR Green qPCR. n = 3 biological replicates; statistical analysis (t tests)
was conducted with GraphPad Prism software: *P < 0.05; **P < 0.01. Data expressed as mean value ± s.e.m. (C) Representative Western Blot of FECH
and GAPDH after a single transfection at 500 nM in K562 cells after 24 or 48 h treatments; corresponding graph plot from n = 3 biological replicates;
statistical analysis (one-way Anova) was conducted with GraphPad Prism software: *P < 0.05 compared to mock treatments. Data expressed as mean
value ± s.e.m.
± 22 ng/mg tissue) and lung (27 ± 8 versus 10 ± 3 ng/mg
tissue), and markedly improved delivery to bone marrow
(224 ± 87 versus 35 ± 12 ng/mg tissue) in line with its pre-
viously described properties (24).
We investigated the metabolic fate of the four SSOs after
repeated administration in vivo. Tissue samples were pro-
cessed using an OTX Clarity Kit and eluates were collected
from kidney, liver, spleen, lung, brain and bone marrow.
The extraction protocol worked poorly for samples con-
taining ORNch, which was remedied by pre-treatment with
proteinase K. Reference LC–MS spectra were generated by
spiking SSOs into eluates collected from tissues from saline-
treated mice. This permitted unambiguous identification
and qualitative analysis of oligonucleotide-derived peaks
in the chromatograms from samples from treated animals
(Figure 6A). Deconvolution of the mass spectra returned
molecular weights from which the structures of metabolites
were inferred (Figure 6B; Supplementary Figures S9–S12).
Intact ORN1 was detected in all the tissues except the
brain, accompanied by 5–10% of the (n – 1)-metabolite cor-
responding to loss of the 3′-terminal nucleotide (metabo-
lite A). In contrast, all of the SSO conjugates showed frag-
mentation. Despite its high stability in mouse plasma, fully
intactORNst was only detected in trace amounts in the liver
sample: hydrolysis of the stearoyl group was seen in all tis-
sues (metaboliteB), togetherwithminor amounts of the 3′(n
– 1)-metabolite (C). Since the stearoyl group of this SSO
was stable in plasma (Figure 4D), it seems possible that its
metabolism occurred at the site of accumulation, or intra-
cellularly. Similar toORNst,ORN84 was not found intact in
any tissues and the majority of its metabolites derived from
progressive cleavage of the peptide. The major metabolite in
liver, kidney, lung and bone marrow was the SSO attached
to the terminal cysteine residue (H and I), whereas partial
cleavage of the peptide occurred in spleen (metabolite G,
possibly with E and F). ORNch was the most resistant of
the series, and delivered a strong signal for intact ORNch
from kidney, liver and spleen samples; the SSO was also de-
tectable in lung and in bone marrow in lower amounts. In-
terestingly, cleavage of the PS-linkage to yield ORN1 and
its 3′-truncated fragment (A) was observed in samples from
kidney, liver and spleen as well as bone marrow.
Effects of SSOs on FECHRNA splicing in mouse tissues and
organs
As discussed above, splice-switching activity of the SSOs in
treated Emi/wt mice could not be assayed at the protein
level, as the predominant transcript III (Figure 1c) from
the humanized allele lacks exon 3. Therefore, we assayed
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Figure 4. Synthesis of SSO conjugates and their metabolism in mouse plasma. (A) Synthesis routes ofMOE-PS SSO conjugates. The stearic acid conjugate
ORNst was obtained in two steps through coupling of a 5
′-amino C6-phosphoramidite linker, followed by reaction with stearicN-hydroxy succinimide ester
(A); the peptide conjugateORN84 and the cholesterol conjugate (ORNch) were generated in two steps using a 5
′-cagedmaleimidemodifier phosphoramidite
and reaction with the cysteine-modified CD84-peptide (B) or thiocholesterol (C), respectively. (DCA: dichloroacetic acid; MMTr: monomethoxy-trityl).
(B–D) ORN84, ORNch and ORNst were incubated in mouse plasma for 26 h at 37
◦C. Aliquots of plasma were removed periodically, cleaned and anal-
ysed by LC–MS. ORN184 underwent hydrolysis at the peptide and the succinimide linker (b). ORN1ch underwent hydrolysis-mediated ring opening (C).
ORN1st was barely affected under the conditions (D). Red arrows indicate inferred sites of cleavage, based upon the masses of fragments in the LC–MS
chromatagrams.
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Figure 5. Characterization of SSOs and their accumulation in selected tissues. (A) Principle of CL-qPCR (53). Two chemically modified PCR primers ‘PS’
and ‘PBS’ are added to a sample containing the chemically modified SSO and incubated for 1 h at 30◦C. Hybridization of the primers to the SSO lead to
formation of a DNA strand, which serves as template for quantitative PCR. (B) Quantification using CL-qPCR of target oligonucleotidesORN1,ORNch,
ORNst and ORN84 in kidney, liver, bone marrow, spleen and lung. Animals received four injections at 50 mg/kg in 0.9% saline over 2 weeks and were
sacrificed 24 h after the last dose. n = 4; data expressed as mean value ± s.e.m.; p = present (detectably higher than NTC, but not quantifiable).
SSO activity by the increase in the correctly-spliced tran-
script I by using SBYR Green RT-qPCR. Splice correc-
tion of the FECH transgene by SSOs was observed in kid-
ney, liver, bone marrow, spleen and lung, with varying effi-
ciency; we detected no increases in the correct transcript in
spleen, heart and gastrocnemius muscle (Figure 7). The hu-
man aberrant FECH transcript is a substrate for NMD and
therefore is unstable in vivo (3). Nevertheless, we assayed
the aberrant/correct splice ratios in the liver sample using
RT-PCR. The data correlated with that from the RT-qPCR
measurements for three out of four SSOs (ORN1, ORNst,
ORNch) (Supplementary Figure S13).
For single-stranded PS oligonucleotides, kidney is the
main site of accumulation (Figure 5B) (15,58). The stearoyl
conjugate ORNst was most effective in liver (1.6-fold) and
in lung, two tissues in which the conjugated group increased
accumulation (Figure 5B).ORN84, which was found at 6.5-
fold higher levels in bone marrow (Figure 5B), did not show
significantly better splice-modulating activity than ORN1
(Figure 7).
From the three SSO conjugates, ORNch provided the
most promising results. Surprisingly, it did not exhibit supe-
rior activity to that ofORN1 in liver nor in kidney. This was
unexpected since cholesterol conjugates are a well-known
means to boost the activities of antimiR oligonucleotides in
liver (21) (ORNch exhibited a 7-fold increase in liver; Figure
5B). Most importantly, however, ORNch showed a 1.8-fold
increase in the FECH transcript in bone marrow compared
to ORN1, with a similar level of accumulation. Since most
of the FECH transcripts in the bonemarrow likely originate
from erythroblasts, the increase in correctly spliced FECH
mRNA strongly suggests a successful uptake of the SSO by
erythroblasts.
DISCUSSION
Loss-of-function (LoF) mutations that result in reduced or
abolished protein function represent a common cause of ge-
netic disorders. Many of these result from defective splic-
ing events (59). It is difficult to discover or design conven-
tional small-molecule drugs to correct defective splicing in
a sequence-selective manner. However, oligonucleotides are
well suited tomodulatemRNA splicing since they bindwith
high selectivity directly to the disease-causing element. Con-
sequently, there is considerable excitement for a wave of
SSOs that are currently in pre-clinical and clinical develop-
ment (31,60–62).
Splice-switching mechanisms differ fundamentally from
terminating mechanisms for oligonucleotide therapies. For
the latter, the drug is typically optimized to provide a max-
imum inhibition of the target; for the former, the objective
is to increase expression of the target to counter a loss of
function. For many LoF diseases, even a small increase in
levels of the target protein can be therapeutically beneficial
(63,64). This applies to EPP where it is thought that rais-
ing FECH protein/enzyme activity by 10–20% may be suf-
ficient to provide therapeutic benefit to patients (9). The de-
velopment of an oligonucleotide therapy for EPP is espe-
cially desirable since nearly all patients exhibit the same in-
tronic SNP variant. On the other hand, an oligonucleotide
therapy for EPP requires the delivery of the SSO into ery-
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Figure 6. Metabolites of SSOs ORN1, ORNst, ORN84 and ORNch from tissues after administration to Emi/wtmice. (A) Animals received four injections
at 50 mg/kg in 0.9% saline over 2 weeks and were sacrificed 24 h after the last dose. Oligonucleotides were extracted from the tissue matrix using the Phe-
nomenex Clarity OTX kit. Tissues from mice treated withORN1ch were subjected to a proteinase K digestion before processing. Detected oligonucleotide
species are marked in red, next to their associated masses determined by LC–MS (see also Supplementary Figures S9–S12). (B) Calculated molecular
weights of parent SSOs and their inferred metabolites from LC–MS data shown in a) (C17 is the stearoyl chain; chol is the thiocholesteryl group).
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Figure 7. Treatment of Emi/wt mice with SSOs modulates splicing in selected tissues. Animals received four injections at 50 mg/kg in 0.9% saline over
2 weeks and were sacrificed 24 h after the last injection. Levels of correct FECH transcript were assessed by SYBR green RT-qPCR and normalized to
GAPDH and to the saline group. n = 3 animals for the saline group; n = 4 animals for oligonucleotide treated groups; statistical analysis (t tests) was
conducted with GraphPad Prism software: *P < 0.05; **P < 0.01 (whiskers indicate lowest and highest values; middle line represents the median).
throcyte precursors in the bone marrow and with an effi-
ciency to counter the rapid pace of erythrocyte biogenesis.
In this study, we identified PS-MOE SSOs that bind to
the c.315-48 SNP and redirect the splicing of FECH, al-
most completely to the correct form in cell models. It is
likely that the SSO blocks an EIE at the site of the SNP.
We conjugated the SSO to three classes of targeting groups
(cholesterol, fatty acids, peptides) and administered them to
a mouse model of EPP in order to study their distribution,
their metabolic stability and their FECH splice-switching
ability. The conjugated groups exhibited distinct distribu-
tion profiles, notably increasing SSO delivery to liver, kid-
ney, bone marrow and lung. A variety of sensitive tech-
niques have emerged recently for the detection and quantifi-
cation of oligonucleotides in biological samples (27,65,66).
We employed CL-qPCR to quantify the SSOs in tissues
and recorded similar values to those reported using other
methods (10’s-100’s ng/mg tissue). Whereas the PS-MOE
oligonucleotide was highly stable, the conjugates were heav-
ily metabolized in vivo, particularly the amide linkage of
ORNst, which was unexpected given its common use in drug
conjugates (67–69). This metabolism likely occurred after
clearance from circulation, since amide cleavage was not
observed in the mouse plasma assay. The most robust SSO
in vivo was ORNch, which did not boost the accumulation
in bone marrow but nevertheless increased levels of cor-
rectly spliced FECH transcript by 80%. It is presently un-
known whether a 1.8-fold increase in FECH transcript lev-
els would produce a therapeutically-meaningful outcome,
i.e. would lower circulating PPIX. However, the experi-
ments performed in the K562 cells are encouraging, where
a 30% increase of correctly spliced RNA raised levels of
FECH protein by 50% (Figure 3B, C). Clarity on this ques-
tionwill be available froman improvedmousemodel of EPP
(ongoing), i.e. expressing the same FECH transcripts (I and
II in Figure 1C) present in EPP patients.
In this study, we quantified SSO accumulation and splice
switching data in six tissues of the mouse by four SSOs.
In order to affect splice switching, an SSO must reach the
target tissue, be taken up by the appropriate cells, escape
from intracellular compartments and traffic to the nucleus
so as to bind the target pre-mRNA. One expects that the
conjugate groups––and their metabolism––will affect these
individual steps in various ways. Therefore, it was not un-
expected that for these four structurally-distinct SSOs tis-
sue accumulation did not correlate collectively with splice-
switching activity.
The recent approval of several breakthrough oligonu-
cleotide therapeutics signifies that RNA can today be con-
sidered as amainstream class of drugs and drug targets. The
oligonucleotides are single- or double-stranded, of various
chemistries and they elicit their action upon well-validated
mRNA targets expressed in the liver and the central ner-
vous system. Extending the use of SSO therapies to the bone
marrow, for example for EPP or other disorders, would sig-
nificantly advance the oligonucleotide field.
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22. Krützfeldt,J., Kuwajima,S., Braich,R., Rajeev,K.G., Pena,J.,
Tuschl,T., Manoharan,M. and Stoffel,M. (2007) Specificity, duplex
degradation and subcellular localization of antagomirs. Nucleic Acids
Res., 35, 2885–2892.
23. Wolfrum,C., Shi,S., Jayaprakash,K.N., Jayaraman,M., Wang,G.,
Pandey,R.K., Rajeev,K.G., Nakayama,T., Charrise,K.,
Ndungo,E.M. et al. (2007) Mechanisms and optimization of in vivo
delivery of lipophilic siRNAs. Nat. Biotech., 25, 1149–1157.
24. Nowakowski,G.S., Dooner,M.S., Valinski,H.M., Mihaliak,A.M.,
Quesenberry,P.J. and Becker,P.S. (2004) A specific heptapeptide from
a phage display peptide library homes to bone marrow and binds to
primitive hematopoietic stem cells. Stem Cells, 22, 1030–1038.
25. Osborn,M.F., Coles,A.H., Biscans,A., Haraszti,R.A., Roux,L.,
Davis,S., Ly,S., Echeverria,D., Hassler,M.R., Godinho,B.M.D.C.
et al. (2019) Hydrophobicity drives the systemic distribution of
lipid-conjugated siRNAs via lipid transport pathways. Nucleic Acids
Res., 47, 1070–1081.
26. Prakash,T.P., Mullick,A.E., Lee,R.G., Yu,J., Yeh,S.T., Low,A.,
Chappell,A.E., Østergaard,M.E., Murray,S., Gaus,H.J. et al. (2019)
Fatty acid conjugation enhances potency of antisense
oligonucleotides in muscle. Nucleic Acids Res., 47, 6029–6044.
27. Boos,J.A., Kirk,D.W., Piccolotto,M.-L., Zuercher,W., Gfeller,S.,
Neuner,P., Dattler,A., Wishart,W.L., Von Arx,F., Beverly,M. et al.
(2013) Whole-body scanning PCR; a highly sensitive method to study
the biodistribution of mRNAs, noncoding RNAs and therapeutic
oligonucleotides. Nucleic Acids Res., 41, e145.
28. Li,M., Lightfoot,H.L., Halloy,F., Malinowska,A.L., Berk,C.,
Behera,A., Schumperli,D. and Hall,J. (2017) Synthesis and cellular
activity of stereochemically-pure 2[prime or
minute]-O-(2-methoxyethyl)-phosphorothioate oligonucleotides.
Chem. Commun., 53, 541–544.
29. Maruyama,R. and Yokota,T. (2018) Tips to design effective
splice-switching antisense oligonucleotides for exon skipping and
exon inclusion.Methods Mol. Biol., 1828, 79–90.
30. Aartsma-Rus,A. (2012) In: Aartsma-Rus,A (ed). Exon Skipping:
Methods and Protocols. Humana Press, Totowa, NJ, pp. 117–129.
31. Sinha,R., Kim,Y.J., Nomakuchi,T., Sahashi,K., Hua,Y., Rigo,F.,
Bennett,C.F. and Krainer,A.R. (2018) Antisense oligonucleotides
correct the familial dysautonomia splicing defect in IKBKAP
transgenic mice. Nucleic Acids Res., 46, 4833–4844.
32. Darras,B.T., Farrar,M.A., Mercuri,E., Finkel,R.S., Foster,R.,
Hughes,S.G., Bhan,I., Farwell,W. and Gheuens,S. (2019) An
integrated safety analysis of infants and children with symptomatic
spinal muscular atrophy (SMA) treated with nusinersen in seven
clinical trials. CNS Drugs, 33, 919–932.
33. Crooke,S.T., Baker,B.F., Pham,N.C., Hughes,S.G., Kwoh,T.J., Cai,D.,
Tsimikas,S., Geary,R.S. and Bhanot,S. (2018) The Effects of
2′-O-Methoxyethyl oligonucleotides on renal function in humans.
Nucleic Acid Ther., 28, 10–22.
34. Martinez-Nunez,R.T., Wallace,A., Coyne,D., Jansson,L., Rush,M.,
Ennajdaoui,H., Katzman,S., Bailey,J., Deinhardt,K.,
Sanchez-Elsner,T. et al. (2017) Modulation of nonsense mediated
decay by rapamycin. Nucleic Acids Res., 45, 3448–3459.
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